- Covidien pharma president Wright bows out
Timothy Wright resigned as Covidien plc’s (NYSE:COV) senior vice president and president of its pharmaceuticals segment, effective Dec. 2, according to a Securities & Exchange Commission filing. Pharma CFO Matthew Harbaugh will serve as interim president of the segment until Wright’s successor is found, according to the filing.
The first half of 2010 has been brutal for pharmaceutical sales representatives. There are hordes of former pharma sales representatives on the street, seeking new job opportunities. Many try to seek higher ground in the medical device industry, often with limited success.
There is a persistent stigma that pharmaceutical sales representatives cannot succeed as medical device reps. Some of the perceptions that contribute to this are:
By Mary Vanac
Great Lakes Pharmaceuticals Inc. closed a $3.1 million Series B equity offering led by Charter Life Sciences, the Palo Alto, Calif.-based venture capital firm with an office in Cincinnati.
The company, formed by Case Western Reserve University, University Hospitals Case Medical Center and Ricerca Biosciences LLC in 2005, plans to use the investment to complete a pivotal clinical study of B-Lock, its anti-microbial catheter lock solution.
By Chris Seper
Three Pennsylvania companies — a diagnostics business, an imaging company and another creating a treatment for head lice — were among nine businesses to receive a share of $1.8 million from Ben Franklin Technology Partners of Southeastern Pennsylvania.
The proposed merger between WuXi PharmaTech (Cayman) Inc. (NYSE:WX) and Charles River Laboratories International Inc. (NYSE:CRL) hit another snag after the Federal Trade Commission asked both companies for more information on the deal.
The request, detailed in a pair of regulatory filings, involves the viral clearance services, cell line characterization services and lot release testing services businesses of both companies
SurModics Inc. (NSDQ:SRDX) reached a deal to license its drug delivery technology to an Australian firm that will use it for a skin disorder treatment.
PharmacoPhotonics Inc. raised $1.5 million in equity to develop a device that measures kidney function.
The company’s device can provide a measure of the kidney’s function, or glomerular filtration rate, in 15 to 30 minutes. Current methods of determing GFR either provide a rough estimate or require collecting a patient’s urine samples over a 24-hour period.
Stryker Corp. (NYSE:SYK) expanded the number of seats on its board of directors to nine with the addition of the CEO of Belgian biopharm firm Roch Doliveux.
Kalamazoo, Mich.-based Stryker said Doliveux, UCB’s CEO and executive committee chairman since 2005, is the former CEO of Pierre Fabre Pharmaceuticals and former president of Schering-Plough International.
The largest individual shareholder of Charles River Laboratories International Inc. (NYSE:CRL) has deep reservations about the company’s proposed acquisition of WuXi (Cayman) PharmaTech Inc. (NYSE:WX) and they’re not shy letting their position be known.
United BioSource Corp. bought Lexington, Mass.-based life sciences consultancy Abt Bio-Pharma Solutions Inc. for an undisclosed amount.
The Abt Associates subsidiary provides health economics and outcomes research, registries and observational studies and market access solutions to the medical device, biopharmaceutical and diagnostics industries.
Echo Therapeutics Inc. (OTC:ECTE) and Ferndale Pharma Group Inc. enrolled the first patients in a clinical trial of Echo’s Prelude SkinPrep device and Ferndale’s 4 percent topical lidocaine, ahead of an application for 510(k) clearance for the drug-device combo from the Food & Drug Administration.
Franklin, Mass.-based Echo’s Prelude device is a needle-free, transdermal drug delivery system that ablates a thin layer of skin before a drug is applied.